In context
Pentapeptide-18 was chemically modified with terminal D-tyrosine in a laboratory study of pigment production in melanocytes and a reconstructed skin model. [1]
At a glance
- Type
- Topical cosmetic ingredient
- Regulatory context
- The cited source describes research, not a determination of present marketing authorisation. Country, formulation and indication must be checked separately.
- Evidence
- The modified molecule and the unmodified commercial ingredient are not interchangeable. Laboratory pigment changes do not establish a human treatment effect.
How to interpret this evidence
The modified molecule and the unmodified commercial ingredient are not interchangeable. Laboratory pigment changes do not establish a human treatment effect. [1]
Safety and clinical context
Topical cosmetic research does not support injection or other systemic use. Safety and tolerability depend on the complete formulation and the person using it.
Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.
Primary sources
Read the underlying source and its limitations. A study citation does not by itself establish efficacy or approval.
- D-tyrosine adds an anti-melanogenic effect to cosmetic peptides. pubmed.ncbi.nlm.nih.gov